RFS was shorter in KRAS mutated patients without a statistical significance (mRFS 25.84 months vs. 31.99 months; p=0.23) suggesting that the KRAS mutation may have a deleterious effect and that the tumor cells may be inherently resistant to adjuvant therapies. This evidence concerns the gene KRAS and neoplasm.